Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 2/20 | 0.41 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.38 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.37 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.37 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.37 |
| ▸ | MTOR | P42345 | 1/20 | 0.37 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.34 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5853395 | 0.85 | GABRA1 (0.46) | GABRA1GABRB2TAAR1KDM4EALDH1A1 | |
| SCHEMBL620083 | 0.85 | TAAR1 (0.42) | GABRA1TAAR1PDCD1CD274KDM4E | |
| SCHEMBL16961004 | 0.84 | GABRA1 (0.50) | GABRA1GABRB2PDCD1CD274ALDH1A1 | |
| SCHEMBL320965 | 0.83 | GABRA1 (0.46) | GABRA1GABRB2TAAR1KDM4EGAA | |
| SCHEMBL13180248 | 0.81 | GABRA1 (0.43) | GABRA1GABRB2TAAR1PDCD1CD274 | |
| SCHEMBL16587908 | 0.81 | GABRA1 (0.38) | GABRA1GABRB2TAAR1KDM4EGAA | |
| SCHEMBL460389 | 0.80 | GABRA1 (0.52) | GABRA1GABRB2TAAR1PDCD1CD274 | |
| SCHEMBL91337 | 0.79 | KDM4E (0.45) | GABRA1GABRB2TAAR1KDM4EGAA | |
| SCHEMBL17857328 | 0.79 | HTT (0.39) | GABRA1GABRB2TAAR1KDM4EGAA | |
| SCHEMBL17858593 | 0.79 | HTT (0.39) | GABRA1GABRB2TAAR1KDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115698017-A | Methyl 2-methyl-5-oxo-1, 4,5, 7-tetrahydrofuro [3,4-b ] pyridine-3-carboxylate compounds as CAV1.2 activators | 诺华股份有限公司 | 2023-02-03 | — | — | CN | disclosed |
| WO-2021255608-A1 | METHYL 2-METHYL-5-OXO-1,4,5,7-TETRADHYDROFURO[3,4- B]PYRIDINE-3-CARBOXYLATE COMPOUNDS AS CAV1.2 ACTIVATORS | NOVARTIS AG (CH) | 2021-12-23 | — | — | WO | disclosed |
| US-20210387995-A1 | METHYL 2-METHYL-5-OXO-1,4,5,7-TETRADHYDROFURO[3,4-b]PYRIDINE-3-CARBOXYLATE COMPOUNDS AS CAV1.2 ACTIVATORS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2021-12-16 | — | — | US | disclosed |
| EP-3233839-B1 | HETEROCYCLYL LINKED IMIDAZOPYRIDAZINE DERIVATIVES AS PI3KBETA INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-09-25 | — | — | EP | disclosed |
| US-10202387-B2 | Heterocyclyl linked imidazopyridazine derivatives as PI3KB inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2019-02-12 | — | — | US | disclosed |
| US-20180057496-A1 | HETEROCYCLYL LINKED IMIDAZOPYRIDAZINE DERIVATIVES AS PI3KB INHIBITORS | JANSSEN-CILAG (FR) | 2018-03-01 | — | — | US | disclosed |
| US-20180057496-A1 | HETEROCYCLYL LINKED IMIDAZOPYRIDAZINE DERIVATIVES AS PI3KB INHIBITORS | JANSSEN-CILAG (FR) | 2018-03-01 | — | — | US | disclosed |
| US-20180002336-A1 | IMIDAZOPYRIDAZINE DERIVATIVES AS PI3KB INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-01-04 | — | — | US | disclosed |
| EP-2900645-A1 | 3-PHENYLISOXAZOLIN DERIVATIVES WITH HERBICIDAL ACTION | Bayer CropScience AG (DE) | 2015-08-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10202387-B2 | Heterocyclyl linked imidazopyridazine derivatives as PI3KB inhibitors | PIK3CB, PIK3CD, PIK3CA | GABRA1 1489/4885GABRB2 596/4885TAAR1 4834/4885 |
| US-20180002336-A1 | IMIDAZOPYRIDAZINE DERIVATIVES AS PI3KB INHIBITORS | PIK3CB, PIK3CD, PIK3CA | GABRA1 1118/4885GABRB2 624/4885TAAR1 4772/4885 |
| US-20210387995-A1 | METHYL 2-METHYL-5-OXO-1,4,5,7-TETRADHYDROFURO[3,4-b]PYRIDINE-3-CARBOXYLATE COMPOUNDS AS CAV1.2 ACTIVATORS | CACNA1D, CACNA1I, CACNA1S | GABRA1 273/4885GABRB2 236/4885TAAR1 644/4885 |
| US-20180057496-A1 | HETEROCYCLYL LINKED IMIDAZOPYRIDAZINE DERIVATIVES AS PI3KB INHIBITORS | PIK3CB, PIK3CD, PIK3CA | GABRA1 1489/4885GABRB2 596/4885TAAR1 4834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.